Literature DB >> 14551798

Passive transfer of purified IgG from patients with amyotrophic lateral sclerosis to mice results in degeneration of motor neurons accompanied by Ca2+ enhancement.

A H Pullen1, M Demestre, R S Howard, R W Orrell.   

Abstract

It has been reported that immunoglobulins (IgG) in sera of patients with amyotrophic lateral sclerosis (ALS) kill cultured motoneurones (MN), but whether they also cause MN degeneration in vivo is unclear. To test this, protein-A affinity purified and dialysed IgGs were prepared from sera of 44 ALS patients without paraproteinemias, 20 healthy controls and 15 disease controls. Control and ALS-IgGs were injected intraperitoneally into groups of mice for 5 consecutive days and examined at day 8. IgG was localised immunocytochemically and spinal MN were characterised histologically and ultrastructurally and by comparative counts of Ca(2+) containing organelles revealed with oxylate-pyroantimonate histochemistry. ELISA revealed no differences in IgG concentration between ALS patients and control subjects. Immunocytochemistry showed IgG was present in MN of mice injected with control or ALS-IgG, but densitometry showed immunostaining in MN was stronger in mice injected with ALS-IgG. Compared to MN of non-injected mice, control-IgG-treated mice showed near normal MN morphology and numbers of Ca(2+)-containing organelles. Disease control IgGs evoked negligible or minor morphological changes according to disease, but normal numbers of Ca(2+) containing organelles. Ultrastructurally, about 70% of ALS-derived IgGs induced a population of MN with electron lucent cytoplasm, distended Golgi, disrupted Nissl and mitochondria (i.e., necrosis). However 30% of ALS-IgGs additionally induced electron-dense degeneration in 40% of the MN. These MN exhibited shrinkage, condensed nuclear chromatin and ill-defined nuclear membranes and resembled preliminary stages of apoptosis. We conclude that passive transfer of ALS-derived, but not control IgGs, does result in MN degeneration in the recipient mice. This appears to be associated with abnormal calcium homeostasis, but the exact target of ALS-IgG remains conjectural, and the possibilities are discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14551798     DOI: 10.1007/s00401-003-0777-z

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  19 in total

1.  The C9orf72-interacting protein Smcr8 is a negative regulator of autoimmunity and lysosomal exocytosis.

Authors:  Yingying Zhang; Aaron Burberry; Jin-Yuan Wang; Jackson Sandoe; Sulagna Ghosh; Namrata D Udeshi; Tanya Svinkina; Daniel A Mordes; Joanie Mok; Maura Charlton; Quan-Zhen Li; Steven A Carr; Kevin Eggan
Journal:  Genes Dev       Date:  2018-06-27       Impact factor: 11.361

Review 2.  Plasma and cerebrospinal fluid-based protein biomarkers for motor neuron disease.

Authors:  Christi Kolarcik; Robert Bowser
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

3.  Immunological aspects in amyotrophic lateral sclerosis.

Authors:  Maria Carolina O Rodrigues; Júlio C Voltarelli; Paul R Sanberg; Cesario V Borlongan; Svitlana Garbuzova-Davis
Journal:  Transl Stroke Res       Date:  2012-05-03       Impact factor: 6.829

Review 4.  Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies.

Authors:  Einar M Sigurdsson
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

5.  Calcium signaling pathways mediating synaptic potentiation triggered by amyotrophic lateral sclerosis IgG in motor nerve terminals.

Authors:  Mario R Pagani; Ricardo C Reisin; Osvaldo D Uchitel
Journal:  J Neurosci       Date:  2006-03-08       Impact factor: 6.167

Review 6.  New insights into mitochondrial structure during cell death.

Authors:  Guy Perkins; Ella Bossy-Wetzel; Mark H Ellisman
Journal:  Exp Neurol       Date:  2009-05-21       Impact factor: 5.330

7.  Autoimmunity in amyotrophic lateral sclerosis: past and present.

Authors:  Mario Rafael Pagani; Laura Elisabeth Gonzalez; Osvaldo Daniel Uchitel
Journal:  Neurol Res Int       Date:  2011-08-01

Review 8.  The Role of immune and inflammatory mechanisms in ALS.

Authors:  P A McCombe; R D Henderson
Journal:  Curr Mol Med       Date:  2011-04       Impact factor: 2.222

9.  Recent advances in amyotrophic lateral sclerosis research: perspectives for personalized clinical application.

Authors:  Chen Benkler; Daniel Offen; Eldad Melamed; Lana Kupershmidt; Tamar Amit; Silvia Mandel; Moussa B H Youdim; Orly Weinreb
Journal:  EPMA J       Date:  2010-06-29       Impact factor: 6.543

Review 10.  Interplay between immunity and amyotrophic lateral sclerosis: Clinical impact.

Authors:  Fabiola De Marchi; Ivana Munitic; Amedeo Amedei; James D Berry; Eva L Feldman; Eleonora Aronica; Giovanni Nardo; Donatienne Van Weehaeghe; Elena Niccolai; Nikolina Prtenjaca; Stacey A Sakowski; Caterina Bendotti; Letizia Mazzini
Journal:  Neurosci Biobehav Rev       Date:  2021-06-19       Impact factor: 9.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.